Compare NTAP & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTAP | ZTS |
|---|---|---|
| Founded | 1992 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3B | 32.5B |
| IPO Year | 1996 | 2012 |
| Metric | NTAP | ZTS |
|---|---|---|
| Price | $207.08 | $73.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $116.58 | ★ $154.18 |
| AVG Volume (30 Days) | 2.2M | ★ 5.8M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.91% | 1.86% |
| EPS Growth | ★ 11.99 | 10.05 |
| EPS | ★ 6.35 | 3.08 |
| Revenue | $6,237,000,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | $6.22 | $5.63 |
| Revenue Next Year | $4.91 | $4.77 |
| P/E Ratio | $32.28 | ★ $24.62 |
| Revenue Growth | ★ 5.59 | 2.28 |
| 52 Week Low | $93.69 | $71.45 |
| 52 Week High | $209.06 | $160.48 |
| Indicator | NTAP | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 74.57 | 45.19 |
| Support Level | $97.45 | $73.42 |
| Resistance Level | N/A | $78.74 |
| Average True Range (ATR) | 7.48 | 3.08 |
| MACD | 2.09 | -0.06 |
| Stochastic Oscillator | 91.69 | 28.33 |
NetApp Inc is storage hardware provider into a software-driven, cloud-centric data infrastructure company. Its flagship ONTAP data management software, together with a comprehensive portfolio of all-flash, hybrid-flash, and cloud-native solutions, forms the backbone of digital transformation for thousands of enterprises world'wide. Its operations are organized into two segments Hybrid Cloud and Public Cloud. It generates majority of revenue from Hybrid Cloud offers a unified data storage portfolio of storage management and infrastructure solutions that helps customers modernize their data centers. Hybrid Cloud includes software, hardware, and related support, along with professional and other services. It generates majority of revenue from United States followed by International market.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.